| ID | 117032 |
| Author |
Bando, Hiroshi
Tokushima University|Japan Low Carbohydrate Diet Promotion Association
KAKEN Search Researchers
|
| Keywords | Glucagon-like peptide 1 receptor agonists (GLP-1 RAs)
Oral semaglutide (Rybelsus)
Sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC)
Peptide Innovation for early diabetes treatment (PIONEER)
Adverse effects (AEs)
|
| Content Type |
Journal Article
|
| Description | As one of the Glucagon-like peptide 1 receptor agonists (GLP-1 RAs), oral semaglutide (Rybelsus) become first ingestible agent by absorption enhancer sodium N-(8-[2-hydroxybenzoyl] amino) caprylate (SNAC). It was clinically investigated by Peptide InnOvatioN for Early diabEtes tReatment (PIONEER) trials. Pharmacologically, blood concentration of semaglutide is kept higher when fasting time period after intake becomes longer. It is provided for increasing doses of 3 mg, 7 mg, 14 mg in every month. Rybelsus showed higher ratio of adverse effects (AEs), which include gastrointestinal dysfunction and headache. This agent is a novel delivery of therapeutic peptide and become life-changing beneficial agents for diabetic patients.
|
| Journal Title |
Journal of Diabetes, Obesity & Metabolism
|
| Publisher | Yumed Text
|
| Volume | 5
|
| Issue | 1
|
| Start Page | e108
|
| Published Date | 2022-04-24
|
| Rights | Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (https://creativecommons.org/licenses/by-nc-sa/4.0/).
|
| URL ( Publisher's Version ) | |
| FullText File | |
| language |
eng
|
| TextVersion |
Publisher
|
| departments |
Medical Sciences
|
